BioAge Labs Q2 net loss $21.6M, cash $313.4M; BGE-102 Phase 1 on track for 2H 2025

BioAge Labs, Inc.

2025-Q2 EPS reported -$0.96 revenue$3,863,000

Net loss $21.6M ($0.60/share) vs $13.6M loss in Q2 2024; R&D expenses rose to $19.8M.
Cash and marketable securities $313.4M as of June 30, 2025; runway through 2029.
BGE-102 IND-enabling completed; Phase 1 SAD/MAD starts 2H 2025 with data by year-end.
Option agreement for APJ agonist nanobody with >10x apelin potency; oral APJ patent filed.
Launched HUNT Biobank collaboration to profile 17,000+ samples for aging biology.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.